Brian D Crompton
Overview
Explore the profile of Brian D Crompton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gillani R, Shulman D, DelRocco N, Klega K, Han R, Krailo M, et al.
medRxiv
. 2025 Feb;
PMID: 39974064
Purpose: Identification of discrete sub-groups associated with treatment response and resistance in localized Ewing sarcoma (EWS) remains a challenge. The primary objective of the Children's Oncology Group biology study AEWS18B1-Q...
2.
Gillani R, Collins R, Crowdis J, Garza A, Jones J, Walker M, et al.
Science
. 2025 Jan;
387(6729):eadq0071.
PMID: 39745975
Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric extracranial solid tumors using germline...
3.
Laetsch T, Voss S, Ludwig K, Hall D, Barkauskas D, Dubois S, et al.
J Clin Oncol
. 2024 Dec;
:JCO2401854.
PMID: 39652801
Purpose: The TRK inhibitor larotrectinib is US Food and Drug Administration approved for fusion-positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been...
4.
Gillani R, Collins R, Crowdis J, Garza A, Jones J, Walker M, et al.
bioRxiv
. 2024 May;
PMID: 38746320
Pediatric solid tumors are rare malignancies that represent a leading cause of death by disease among children in developed countries. The early age-of-onset of these tumors suggests that germline genetic...
5.
Mittal K, Cooper G, Lee B, Su Y, Skinner K, Shim J, et al.
Commun Biol
. 2024 Apr;
7(1):426.
PMID: 38589567
Wilms tumor (WT) is the most common renal malignancy of childhood. Despite improvements in the overall survival, relapse occurs in ~15% of patients with favorable histology WT (FHWT). Half of...
6.
Martin-Giacalone B, Li H, Scheurer M, Casey D, Dugan-Perez S, Marquez-Do D, et al.
JAMA Netw Open
. 2024 Mar;
7(3):e244170.
PMID: 38546643
Importance: Determining the impact of germline cancer-predisposition variants (CPVs) on outcomes could inform novel approaches to testing and treating children with rhabdomyosarcoma. Objective: To assess whether CPVs are associated with...
7.
Bourgeois W, Cutler J, Aubrey B, Wenge D, Perner F, Martucci C, et al.
Blood
. 2023 Dec;
143(15):1513-1527.
PMID: 38096371
Small molecules that target the menin-KMT2A protein-protein interaction (menin inhibitors) have recently entered clinical trials in lysine methyltransferase 2A (KMT2A or MLL1)-rearranged (KMT2A-r) and nucleophosmin-mutant (NPM1c) acute myeloid leukemia (AML)...
8.
Yang D, Zhou Q, Furman-Cline L, Cheng X, Luo D, Lai H, et al.
JCO Clin Cancer Inform
. 2023 Nov;
7:e2300104.
PMID: 37956387
Purpose: Osteosarcoma research advancement requires enhanced data integration across different modalities and sources. Current osteosarcoma research, encompassing clinical, genomic, protein, and tissue imaging data, is hindered by the siloed landscape...
9.
Shulman D, Merriam P, Choy E, Guenther L, Cavanaugh K, Kao P, et al.
Cancer Med
. 2023 Jun;
12(14):15207-15216.
PMID: 37306107
Background: Ewing sarcoma (EWS) is an aggressive sarcoma with few treatment options for patients with relapsed disease. Cyclin-dependent kinase 4 (CDK4) is a genomic vulnerability in EWS that is synergistic...
10.
Marinoff A, Spurr L, Fong C, Li Y, Forrest S, Ward A, et al.
JCO Precis Oncol
. 2023 Mar;
7:e2200334.
PMID: 36996377
Purpose: Osteosarcoma risk stratification, on the basis of the presence of metastatic disease at diagnosis and histologic response to chemotherapy, has remained unchanged for four decades, does not include genomic...